Companion Biomarkers in Drug Development - Action News 5 - Memphis, Tennessee

Companion Biomarkers in Drug Development

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, February 3, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/rdf8hb/companion) has announced the addition of the "Companion Biomarkers in Drug Development" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Companion biomarkers are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. 

Market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. Using companion biomarkers yields safer and more efficacious drug products, reduces clinical trial and development costs, improves post-marketing safety profiles and salvages therapies that otherwise would not be granted approval. 

This report focuses on the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. This report also examines companies that are actively developing and marketing companion biomarkers around the world. Detailed tables and charts with sales forecasts and marketshare data are also included. 


Key Topics Covered: 

1. Overview

2. Introduction: Companion Diagnostics in Drug Development

3. Biomarker Development Tools

4. Market for Biomarkers in Drug Development

5. Imaging Biomarkers in Drug Discovery

6. Clinical Biomarkers Improving Trial Design

7. Biomarkers as Surrogate Endpoints

8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development 

9. Regulatory Issues for Biomarkers in Drug Development 

10. Business Decisions Using Companion Biomarkers in Drug Development

11. Company Profiles 


Companies Mentioned:

  • Abbott Laboratories
  • Biotrin (DiaSorin)
  • Bristol-Myers Squibb Company
  • DiagnoSwiss
  • Exiqon A/S
  • Gyros AB
  • HealthCare IT
  • High Throughput Genomics
  • Ipsen
  • Jerini AG
  • Johnson & Johnson
  • KOOPrime
  • Koada Technology
  • LINCO Research
  • Life Technologies Corporation
  • Luminex
  • MDS, Inc (Nordion, Inc)
  • Novartis
  • Nuvera Biosciences
  • Ocimum Biosolutions
  • Pub Gene
  • Qiagen
  • Radix BioSolutions
  • Sygnis Pharma AG
  • TG Services, Inc
  • Ventana Medical Systems
  • ViaLogy
  • Wyeth
  • Zeptosens
  • Zeus Scientific
  • Zyagen



For more information visit http://www.researchandmarkets.com/research/rdf8hb/companion


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow